This Clinical Insights summarizes the pharmacological characteristics of dalbavancin and oritavancin and evaluates the clinical evidence supporting their use in infections beyond acute bacterial skin and skin structure infections for general internal medicine clinicians.
No takes yet. Share an insight, caveat, or question.
Pallotta et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: